{"id":18064,"date":"2025-05-15T20:27:55","date_gmt":"2025-05-16T00:27:55","guid":{"rendered":"https:\/\/qprn.ca\/?p=18064"},"modified":"2026-04-08T15:31:25","modified_gmt":"2026-04-08T19:31:25","slug":"quebec-consortium-on-treatment-efficacy-and-safety","status":"publish","type":"post","link":"https:\/\/qprn.ca\/en\/2025\/05\/15\/quebec-consortium-on-treatment-efficacy-and-safety\/","title":{"rendered":"Quebec Consortium on Treatment Efficacy and Safety"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Objective<\/h2>\n\n\n\n<p>The Consortium on Treatment efficacy and safety aims to study all aspects of efficacy and safety, taking into account all the different factors and various contexts of use, with the goal of offering a personalized therapeutic strategy to the majority of people. Over the next few years, efforts will be made to enhance knowledge in the following themes, among others:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>therapeutic profile of laboratory-tested treatments improvement;<\/li>\n\n\n\n<li>cannabis usage;<\/li>\n\n\n\n<li>polypharmacy and polytherapy;<\/li>\n\n\n\n<li>big data analysis.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">GOVERNANCE<\/h2>\n\n\n\n<p>Each consortium operates on three levels:<\/p>\n\n\n\n<p><strong>i. Consortium Directors <\/strong>: <a href=\"https:\/\/qprn.ca\/en\/investigator\/eric-troncy\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u00c9ric Troncy<\/a>, researcher at Universit\u00e9 de Montr\u00e9al, <a href=\"https:\/\/qprn.ca\/en\/investigator\/melanie-berube\/\" target=\"_blank\" rel=\"noreferrer noopener\">M\u00e9lanie B\u00e9rub\u00e9<\/a>, researcher at Universit\u00e9 Laval, <a href=\"https:\/\/qprn.ca\/en\/investigator\/laurent-dupuis\/\" target=\"_blank\" rel=\"noreferrer noopener\">Laurent Dupuis<\/a>, patient partner and <a href=\"https:\/\/qprn.ca\/en\/investigator\/annie-levesque\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annie Levesque<\/a>, patient partner. The consortium directors are supported by the QPRN scientific committee.<\/p>\n\n\n\n<p><strong>ii. QPRN Scientific Committee<\/strong><\/p>\n\n\n\n<p><strong>iii. The larger group<\/strong> is composed of student representatives,  people from research and clinical backgrounds as well as any other person with expertise relevant to the work. Anyone with an interest in the field of pain is encouraged to participate in the consortium&#8217;s meetings and activities. It is also possible to participate in more than one consortium. The trainee representatives are Claudie Audet and Alexa Coulombe-Lev\u00eaque.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Progress<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>January 19, 2024<\/strong>, Mount Sainte-Anne. Launch of the new consortium and large-group discussion meeting that led to a first team project funding. This project focuses on deprescription of gabapendinoids.<\/li>\n\n\n\n<li><strong>October 11, 2024<\/strong>, Drummondville. QPRN organized the first in person meeting of this consortium. At this gathering, two projects were selected for funding, focusing respectively on experiential and clinical perspectives of opioid deprescription, and pain management strategies for adults receiving palliative care. Members also emphasized the importance of exploring pharmacoeconomics, nutrition, needs and ways of evaluating treatment effectiveness that differ depending on the life stage.<\/li>\n\n\n\n<li><strong>December 13, 2024<\/strong>. Launch of a call for projects aiming the research teams and priorities identified at previous meetings. This call led to the selection of two new projects to be funded, focusing respectively on a fundamental approach to understanding the efficacy of analgesics in aging, and a study of the perspective of people living with pain in terms of deprescription approaches.<\/li>\n\n\n\n<li><strong>October 21, 2025, Qu\u00e9bec<\/strong>. Large-group in-person meeting. Thanks to our partners INESSS, the <em>R\u00e9seau qu\u00e9b\u00e9cois de recherche sur le m\u00e9dicament (RQRM)<\/em>, Annie Levesque and Cindy Girard (new patient partners) for their attendance. <\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Projects<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u00e9prescription des gabapentino\u00efdes : approches et perception des personnes vivant avec de la douleur<\/strong> (Line Gu\u00e9nette, M\u00e9lanie B\u00e9rub\u00e9, Magali Millecamps, Laurent Dupuis, Anne-Marie Pinard, Pascal T\u00e9treault, \u00c9ric Troncy, Emily McDonald)<\/li>\n\n\n\n<li><strong>D\u00e9prescription d\u2019opio\u00efdes : Perspectives cliniques et exp\u00e9rientielles sur les besoins en mati\u00e8re d\u2019outils d\u2019accompagnement<\/strong> (L\u00e9onie Archambault, Emily McDonald)<\/li>\n\n\n\n<li><strong>Pain managements strategies in older adults receiving palliative care: a scoping review<\/strong> (M\u00e9lanie B\u00e9rub\u00e9, Lynn Gauthier, \u00c9ric Troncy, Diane Tapp, \u00c9tienne Belzile, Guillaume L\u00e9onard, Line Gu\u00e9nette, Annie Deshaies, Chantal Morency, Norbert Dion, Alexandra Tremblay, St\u00e9phane Pelet)<\/li>\n\n\n\n<li><strong>Est-ce que les m\u00e9dicaments analg\u00e9siques restent efficaces et s\u00e9curitaires au cours du vieillissement<\/strong> (Magali Millecamp, Guillaume L\u00e9onard)<\/li>\n\n\n\n<li><strong>Perception des personnes vivant avec de la douleur chronique sur les approches de d\u00e9prescription<\/strong> (Line Gu\u00e9nette, Ana\u00efs Lacasse, Caroline Sirois, M\u00e9lanie B\u00e9rub\u00e9, Anne-Marie Pinard, \u00c9ric Troncy, Laurent Dupuis)<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Knowledge Mobilisation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Annual retreat 2025 : Update on the current progress and presentation of challenges and opportunities encountered<\/li>\n\n\n\n<li><a href=\"https:\/\/qprn.ca\/en\/2020\/12\/18\/qprn-newsletter\/\" target=\"_blank\" rel=\"noreferrer noopener\">Semestrial newsletter 2025<\/a> : Description of major progress of the consortiums.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Publications<\/h2>\n\n\n\n<p>Details to come<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Partners<\/h2>\n\n\n\n<p>We thank the Canadian Medication Appropriateness and Deprescribing Network for their support and collaboration.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"2192\" height=\"363\" src=\"https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/logo-reseau-deprescription-EN.png\" alt=\"\" class=\"wp-image-18069\" style=\"width:634px;height:auto\" title=\"\" srcset=\"https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/logo-reseau-deprescription-EN.png 2192w, https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/logo-reseau-deprescription-EN-1400x232.png 1400w, https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/logo-reseau-deprescription-EN-768x127.png 768w, https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/logo-reseau-deprescription-EN-1536x254.png 1536w, https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/logo-reseau-deprescription-EN-2048x339.png 2048w\" sizes=\"auto, (max-width: 2192px) 100vw, 2192px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Photos<\/h2>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"662\" height=\"496\" src=\"https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/Image1.jpg\" alt=\"\" class=\"wp-image-18059\" title=\"\"><figcaption class=\"wp-element-caption\">2025 QPRN Retreat<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/IMG_1441-scaled.jpg\" alt=\"\" class=\"wp-image-19608\" title=\"\"><figcaption class=\"wp-element-caption\">Laval University, October 21st, 2025<\/figcaption><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"659\" height=\"494\" src=\"https:\/\/qprn.ca\/wp-content\/uploads\/2025\/05\/Image2.jpg\" alt=\"\" class=\"wp-image-18061\" title=\"\"><figcaption class=\"wp-element-caption\">2024 QPRN Retreat<\/figcaption><\/figure>\n<\/div>\n<\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Objective The Consortium on Treatment efficacy and safety aims to study all aspects of efficacy&#8230;<\/p>\n","protected":false},"author":3,"featured_media":18056,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[38],"class_list":["post-18064","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-scientific-advances","tag-articles-en"],"acf":[],"views":624,"_links":{"self":[{"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/posts\/18064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/comments?post=18064"}],"version-history":[{"count":1,"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/posts\/18064\/revisions"}],"predecessor-version":[{"id":21021,"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/posts\/18064\/revisions\/21021"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/media\/18056"}],"wp:attachment":[{"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/media?parent=18064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/categories?post=18064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/qprn.ca\/en\/wp-json\/wp\/v2\/tags?post=18064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}